{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(19)"],"submitter":["Koehler RC"],"pubmed_abstract":["<h4>Background</h4>The Stroke Preclinical Assessment Network tested 6 therapeutic interventions initiated at the time of reperfusion after focal ischemic stroke in young mice, aging mice, obese mice, and spontaneously hypertensive rats. This randomized, controlled trial was conducted across 6 sites with concealed treatment and blinded neurobehavior assessments. The trial had an adaptive design with preset levels of efficacy and futility interrogated after each of 4 stages. The primary outcome was turning preference on the corner test at 1 month. The PARP (poly(ADP-ribose) polymerase) inhibitor, veliparib, was considered futile after the second stage when pooling all animal models (<i>n</i>=231 veliparib; <i>n</i>=344 placebo).<h4>Methods</h4>A secondary analysis was performed to evaluate v"],"journal":["Journal of the American Heart Association"],"pagination":["e040914"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12684482"],"repository":["biostudies-literature"],"pubmed_title":["Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib."],"pmcid":["PMC12684482"],"pubmed_authors":["Nagarkatti KA","Siddiqui S","Bibic A","Hyder F","Wang K","Erdogan TD","Shi Y","Thedens D","McCullough LD","Nagarkatti K","Goh A","Akhter K","Imai T","Jin X","Ayata C","Beatty HE","Bedirian K","Avery BD","Dawson T","Dawson V","Lo E","Kumskova M","Kimberly WT","Lamb J","Chauhan A","Diaz-Perez S","Van Leyen K","Sansing LH","de Morais AL","Aronowski J","Immakavar E","Yu L","Nisar M","Herman AL","Lyden PD","Dhanesha N","Qin T","Avery B","Obertas L","Dawson TM","Mandeville JB","Boisserand LSB","Sanganahalli BG","Johnson C","Chauhan AK","Mihailovic JM","Karuppagounder SS","Whittier JPW","Koehler RC","Hess DC","SPAN investigators [Link]","Smith C","Diniz MA","Lannon S","Patel RB","Velazquez SE","Dawson VL","Leira EC","Kamat PK","Arbab AS","Jaroslaw Aronowski MD","Dhandapani KM","Huang S","Chen MH","Cao S","Arai K","Khan MB"],"additional_accession":[]},"is_claimable":false,"name":"Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib.","description":"<h4>Background</h4>The Stroke Preclinical Assessment Network tested 6 therapeutic interventions initiated at the time of reperfusion after focal ischemic stroke in young mice, aging mice, obese mice, and spontaneously hypertensive rats. This randomized, controlled trial was conducted across 6 sites with concealed treatment and blinded neurobehavior assessments. The trial had an adaptive design with preset levels of efficacy and futility interrogated after each of 4 stages. The primary outcome was turning preference on the corner test at 1 month. The PARP (poly(ADP-ribose) polymerase) inhibitor, veliparib, was considered futile after the second stage when pooling all animal models (<i>n</i>=231 veliparib; <i>n</i>=344 placebo).<h4>Methods</h4>A secondary analysis was performed to evaluate v","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-06T00:04:35.277Z","creation":"2026-05-23T03:13:25.434Z"},"accession":"S-EPMC12684482","cross_references":{"pubmed":["40996065"],"doi":["10.1161/JAHA.124.040914"]}}